Key Points
- COO Christian Voigtlander sold 8,929 ICU Medical shares at an average price of $182.93, generating approximately $1.63 million. His remaining stake fell 19.28% to 37,377 shares.
- ICU Medical exceeded quarterly expectations, reporting $2.37 EPS versus the $1.91 consensus estimate and revenue of $547.88 million versus $533.44 million expected.
- Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $192.80 target price; institutional investors own approximately 96.1% of the stock.
ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director Elisha Finney sold 378 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the transaction, the director owned 4,871 shares of the company's stock, valued at $888,860.08. This trade represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
ICU Medical Stock Down 0.2%
Shares of NASDAQ ICUI opened at $182.08 on Wednesday. ICU Medical, Inc. has a 12-month low of $107.50 and a 12-month high of $192.85. The company has a market capitalization of $4.55 billion, a PE ratio of 154.31, a price-to-earnings-growth ratio of 2.55 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm's 50-day moving average is $153.69 and its two-hundred day moving average is $141.31.
ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million during the quarter, compared to analysts' expectations of $533.44 million. During the same period last year, the company posted $2.10 EPS. The company's revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.
Hedge Funds Weigh In On ICU Medical
Several institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new position in ICU Medical during the second quarter worth about $26,000. Hilton Head Capital Partners LLC purchased a new stake in ICU Medical in the 4th quarter valued at about $32,000. Covestor Ltd grew its holdings in ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 126 shares during the period. Strs Ohio increased its stake in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its stake in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 146 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
ICUI has been the topic of a number of analyst reports. Needham & Company LLC increased their price objective on ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research note on Friday, August 7th. BTIG Research raised their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday. Wall Street Zen upgraded shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday. Weiss Ratings raised shares of ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Finally, Piper Sandler raised their target price on shares of ICU Medical from $163.00 to $195.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $192.80.
Check Out Our Latest Stock Report on ICU Medical
ICU Medical Company Profile
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
